Share
Services
Fresenius SE & Co. KGaA's subscribed capital amounts to €563,237,277 and consists of 563,237,277 ordinary shares (last change as of 09.06.2022). The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Capitalization
| Date | Capital-related measures | Subscribed Capital / Total number of ordinary Shares |
|---|---|---|
09.06.2022 | Issuance of new shares (scrip dividend) | €563,237,277 / 563,237,277 |
30.11.2021 | Issuance of new shares from stock option plan | €558,502,143 / 558,502,143 |
31.10.2021 | Issuance of new shares from stock option plan | €558,457,143 / 558,457,143 |
30.09.2021 | Issuance of new shares from stock option plan | €558,454,143 / 558,454,143 |
31.08.2021 | Issuance of new shares from stock option plan | €558,453,018 / 558,453,018 |
31.07.2021 | Issuance of new shares from stock option plan | €558,437,193 / 558,437,193 |
30.06.2021 | Issuance of new shares from stock option plan | €558,040,523 / 558,040,523 |
31.05.2021 | Issuance of new shares from stock option plan | €557,716,248 / 557,716,248 |
30.04.2021 | Issuance of new shares from stock option plan | €557,556,509 / 557,556,509 |
31.03.2021 | Issuance of new shares from stock option plan | €557,541,659 / 557,541,659 |
| Date | Capital-related measures | ||
|---|---|---|---|
Subcribed Capital | Nominal Value | Total number of preference shares | Total number of ordinary shares |
2021 | Issuance of new shares from stock option plan | ||
€ 558,502,143 | 558,502,143 | ||
2020 | Issuance of new shares from stock option plan | ||
€ 557,540,909 | 557,540,909 | ||
2019 | Issuance of new shares from stock option plan | ||
€ 557,379,979 | 557,379,979 | ||
2018 | Issuance of new shares from stock option plan | ||
€ 556,225,154 | 556,225,154 | ||
2017 | Issuance of new shares from stock option plan | ||
€ 554,710,473 | 554,710,473 | ||
31.01.2017 | Capital increase from approved capital | ||
€ 553,316,547 | 553,316,547 | ||
2016 | Issuance of new shares from stock option plan | ||
€ 547,208,371 | 547,208,371 | ||
2015 | Issuance of new shares from stock option plan | ||
€ 545,727,950 | 545,727,950 | ||
2014 | Issuance of new shares from stock option plan | ||
€ 541,532,600 | 541,532,600 | ||
01.08.2014 | Stock split with Capital increase from company funds | ||
€ 540,511,632 | 540,511,632 | ||
31.07.2014 | Issuance of new shares from stock option plan | ||
€ 180,170,544 | 180,170,544 | ||
31.07.2014 | Issuance of new shares from stock option plan | ||
€ 180,170,544 | 180,170,544 | ||
2013 | Issuance of new shares from stock option plan | ||
€ 179,694,829 | 179,694,829 | ||
2012 | Issuance of new shares from stock option plan | ||
€ 178,188,260 | 178,188,260 | ||
15.05.2012 | Capital increase from approved capital | ||
€ 177,166,002 | 177,166,002 | ||
30.04.2012 | Issuance of new shares from stock option plan | ||
€ 163,366,002 | 163,366,002 | ||
2011 | Issuance of new shares from stock option plan | ||
€ 163,237,336 | 163,237,336 | ||
28.01.2011 | Unification of share classes | ||
€ 162,450,090 | 162,450,090 | ||
2010 | Issuance of new shares from stock option plan (P&O) | ||
€ 162,450,090 | 81,225,045 | 81,225,045 | |
2009 | Issuance of new shares from stock option plan (P&O) | ||
€ 161,315,376 | 80,657,688 | 80,657,688 | |
2008 | Issuance of new shares from stock option plan (P&O) | ||
€ 161,143,734 | 80,571,867 | 80,571,867 | |
| Capital increase from approval capital | ||
€ 160,863,550 | 80,426,775 | 80,426,775 | |
| Issuance of new shares from stock option plan (P&O) | ||
€ 155,357,436 | 77,678,718 | 77,678,718 | |
2007 | Issuance of new shares from stock option plan (P&O) | ||
€ 155,164,770 | 77,582,385 | 77,582,385 | |
| Share split with capital increase from the Company's funds4 | |||
€ 154,353,876 | 77,176,938 | 77,176,938 | |
2006 | Issuance of new shares from stock option plan (P&O) | ||
€ 131,715,308 | 25,725,646 | 25,725,646 | |
17.11.2006 | Capital increase through contribution in kind (P&O) | ||
€ 131.524.890 | 176,540 | 176,540 | |
2005 | Capital increase from approved capital 9:2 (P&O) | ||
€ 129,849,037 | 25,361,140 | 25,361,140 | |
2005 | Issuance of new shares from stock option plan (P&O) | ||
€ 105,785,037 | 20,661,140 | 20,661,140 | |
2004 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,885,857 | 20,485,519 | 20,485,519 | |
2002 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,882,391 | 20,484,842 | 20,484,842 | |
2001 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,882,043 | 20,484,774 | 20,484,774 | |
| Capital increase through contribution in kind (P&O) | |||
€ 104,800,266 | 20,468,802 | 20,468,802 | |
| Capital increase from corporate funds by new share issue in the ratio 1:1 (P&O) | |||
€ 102,477,865 | 20,015,208 | 20,015,208 | |
| Issuance of new shares from stock option plan (P&O) | |||
€ 51,238,932 | 10,007,604 | 10,007,604 | |
2000 | Issuance of new shares from stock option plan (P&O) | ||
€ 51,238,523 | 10,007,524 | 10,007,524 | |
1999 | Conversion of subscribed capital into € and introduction of non-par shares3 | ||
€ 51,200,000 | 10,000,000 | 10,000,000 | |
1997 | Capital increase (P) | ||
DM 100,000,000 | DM 5 | 10,000,000 | 10,000,000 |
1995 | Change of nominal value from DM 50 to DM 5 | ||
DM 90,000,000 | DM 5 | 8,000,000 | 10,000,000 |
1994 | Capital increase (P) | ||
DM 90,000,000 | DM 50 | 800,000 | 1,000,000 |
1992 | Capital increase / listing (O)2 | ||
DM 80,000,000 | DM 50 | 600,000 | 1,000,000 |
1989 | Capital increase (P) | ||
DM 60,000,000 | DM 50 | 600,000 | 600,000 |
1986 | Listing at Frankfurt Stock Exchange (P)1 | ||
DM 45,000,000 | DM 50 | 300,000 | 600,000 |
1 (P) = Preference Shares
2 (O) = Ordinary Shares
3 Par value per share € 2.56
4 Par value per share € 1.00
105,288,804 shares of total share capital are not listed.
Notification pursuant to Art. 2 (3) Sentence 2 DELEGATED REGULATION (EU) No 2016/1052
Employee participation in our corporate success has a long tradition at Fresenius. In 2023, the employee share program "Fresenius SHARE" was launched. Attached please find an overview of transactions in connection with our employee share program.
| Date | Quantity | Price (€) | Total amount (€) | Detailed overview |
|---|---|---|---|---|
June 3, 2026 | 12,635 | 35.6141 | 449,984.40 | xls-file |
June 2, 2026 | 122,000 | 35.9073 | 4,380,690.00 | xls-file |
June 3, 2025 | 6,754 | 43.8378 | 296,080.20 | xls-file |
June 2, 2025 | 90,000 | 43.4463 | 3,910,171.18 | xls-file |
June 5, 2024 | 9,824 | 29.3653 | 288,484.71 | xls-file |
June 4, 2024 | 80,000 | 29.3091 | 2,344,728.00 | xls-file |
October 6, 2023 | 2,091 | 27.9371 | 58,416.48 | xls-file |
October 5, 2023 | 37,638 | 27.9559 | 1,052,204.16 | xls-file |
Related Links
Interactive ToolDividend policy reflects capital allocation priorities: As part of the full year reporting in February 2025, Fresenius defined a new dividend policy designed to ensure attractive shareholder returns while maintaining strategic flexibility. Going forward, Fresenius will pay out 30 to 40% of its Group core net income excluding Fresenius Medical Care and before special items as dividend.
Fresenius remains fully commitment to delivering attractive shareholder returns. For fiscal year 2025, the Company will propose a dividend of €1.05 per share. This corresponds to a payout ratio of 37%, at the upper half of the 30 to 40% range of core net income1,2, as specified in the Fresenius Financial Framework.
1 Before special items
2 Excluding Fresenius Medical Care
Fill out the fields and click "Show data". The Total Return Calculator will provide you with the current value of your Fresenius shares and the return. Moreover, the Calculator shows the share price performance during the selected period.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
International financial analysts cover Fresenius SE & Co. KGaA and publish reports and updates on the development of its business and its shares. Once a quarter, VARA Research creates an up-to-date consensus from these various forecasts. An interactive and downloadable set of the consensus data for Fresenius SE & Co. KGaA can be found on Vara Research.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolDownload
Fresenius General Credit Presentation
Detailed information for credit investors.
Trends towards a changing geopolitical order have been observable and are still continuing since the beginning of the 2025 fiscal year. The potential implications of this for customs duties, taxes, regulation, administration and political decision-making, for example, may have direct and indirect negative effects on the industry environment and the business activities of the Fresenius Group, although these cannot be estimated at present.
Fresenius will continue to closely monitor the potential impact of increased volatility and reduced visibility on its business and balance sheet.
All of these assumptions are subject to considerable uncertainty. Assumptions to guidance: The company acknowledges that the prevailing trends of fast-moving macroeconomic and geopolitical environment continue, resulting in increased volatility and a higher level of operational uncertainty. The guidance does not take into account potential extreme scenarios that could affect the company, its peers, and the healthcare sector as a whole.
| Fiscal year 2025 (base) | Targets 2026 | |
|---|---|---|
Fresenius Group | ||
Revenue growth (organic)2 | €22,554 m | 4–7% |
Core EPS growth cc3 | €2.87 | 5–10% |
Operating Companies | ||
Fresenius Kabi | ||
Revenue growth (organic)2 | €8,612 m | Mid-to high-single-digit percentage range |
EBIT margin1 | €1,413 m | 16.5% to 17.0% |
Fresenius Helios | ||
Revenue growth (organic) | €13,550 m | Mid-single-digit percentage range |
EBIT margin1 | €1,328 m | 10.0 to 10.5% |
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation.
3 Excluding Fresenius Medical Care and Vitrea
As of May 6, 2026
Related Links
Interactive Tool#CommittedToLife: the health and well-being of patients is Fresenius’ top priority. For more than 100 years, we have been combining cutting-edge technology with a focus on patients, paving the way for the therapies of the future. We save and improve lives and health. We provide access to affordable and innovative medical products and clinical care of the highest quality.
The global healthcare sector is growing and changing rapidly in response to critical challenges driven by demographic shifts, technological advancements and evolving patient needs. These secular growth drivers are here to stay:
Fresenius is part of the solution: We are a relevant, system-critical healthcare company combining innovative medicine, advanced medical technology, and the highest quality in clinical care to shape next-level therapies.
The healthcare sector is one of the world’s largest industries, offering exceptional growth opportunities. We geared our businesses towards these driving forces and are committed to staying at the forefront, ensuring our businesses remain system-relevant and future-ready.
Our unique strengths lie in our positioning: we cover the entire patient journey with a broad portfolio range – right at the critical spots in care – capable of advancing therapies on many levels. With Fresenius Kabi and Fresenius Helios, we address, lead and meet evolving patient needs across three therapy platforms:
With this strategy, we address the driving forces in healthcare that will change the pattern of growth. All business at Fresenius Kabi and Fresenius Helios have leading market positions in attractive markets and grow meaningfully organically. We are part of the solution of innovative healthcare and future therapies:
Since launching #FutureFresenius in October 2022, we have driven structural productivity and improved returns, creating a simpler, more focused, and stronger healthcare company – delivering clear impact for all stakeholders! Key milestones include deconsolidating Fresenius Medical Care, concluding several important strategic portfolio measures, and exiting Vamed.
In 2025, we kicked-off the next phase of #FutureFresenius - Rejuvenate – taking our performance to the next level! In this phase we focus on:
This means bringing new products and innovations to the market, focusing on the needs of patients and customers. We are investing in AI and digital transformation to enhance clinical decision-making, streamline workflows, and improve patient experiences. These next-generation capabilities will strengthen our leadership in medical quality and innovation.
Overview #FutureFresenius strategy:
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Related Links
Interactive Tool
Discover why investing in Fresenius means investing in long-term healthcare innovation. Fresenius is a relevant, system-critical healthcare company. We combine innovative medicine, advanced medical technology, and the highest quality in clinical care to shape next-level therapies.
Watch the video for a quick summary of the key reasons to invest in Fresenius.
Across our therapy platforms, we deliver real impact for patients, professionals, and hospitals around the world. At the same time, we create long-term value for our shareholders.
Explore below a detailed overview of why Fresenius is both – a system-critical healthcare provider and a well-positioned company.
Global healthcare systems are facing critical challenges:
Fresenius is part of the solution: We are actively addressing these global gaps by:
Our unique strength lies in the strong balance between two system-critical businesses: Fresenius Kabi and Fresenius Helios:
Both businesses hold leading market positions in attractive segments and are set for strong, sustainable organic growth and margin expansion.
In October 2022, Fresenius launched its #FutureFresenius strategy. Since then, we have made significant financial and structural progress, making our company more focused, adaptive, and performance driven.
All key financial metrics in Full-Year 2024 compared to Full-Year 2022 improved – a clear sign that our strategy is working.
Visit our Fresenius Annual Report 2024 for more information.
Persistent macroeconomic volatility and emerging geopolitical tensions, Fresenius delivers consistent performance. This reflects the operating strength and continued execution of #FutureFresenius. While serving global markets, we foster a strong local presence. This way we are able to act quickly – also in uncertainties:
We kicked-off the next phase of #FutureFresenius – Rejuvenate – in 2025: Taking our performance to the next level!
Together they offer strong potential for future growth, innovation and digitalization and thus elevating performance.
Fresenius has transformed into a more focused, performance-driven organization with a strong culture of accountability. Our mission stand firm: to save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
With over 100 years of experience, Fresenius has grown from a small business into a global healthcare company. Through #FutureFresenius, we’ve become simpler, more adaptive, and more competitive - delivering real impact to patients, caregivers, hospitals, employees, and shareholders alike. We are ready to lead and remain an employer of choice in today’s competitive healthcare landscape.
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Fresenius Investor Presentation
Fresenius Investor Presentation
